Quark Licenses Alnylam RNAi IP, Vows to End Opposition to IP in Europe, and Pens Deal With Pfizer | GenomeWeb
NEW YORK (GenomeWeb News) – Alnylam Pharmaceuticals has granted Quark Biotech licenses to discover, develop, and commercialize RNAi therapeutics targeting the RTP801 gene for age-related macular degeneration, the companies said yesterday.
 
Simultaneously, Quark has agreed to withdraw its support of opposition to the Kreutzer-Limmer patent estate currently granted in Europe.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.